Incidence, severity, and prevention of infections in chronic granulomatous disease.
We retrospectively analyzed the frequency and nature of infections occurring in 48 patients with chronic granulomatous disease. The long-term use of trimethoprim-sulfamethoxazole and ketoconazole as a preventive therapy for infections has also been evaluated. Lymphadenitis, lung infections, dermatitis, enteral infections, and hepatic abscesses were the most frequent infections. Staphylococcus aureus, Salmonella, and Aspergillus were the main microorganisms encountered. Twelve patients died: five from lung aspergillosis, three from hepatic abscesses, two from pneumonopathy of unknown origin, one from salmonellosis, and one from another probable infection that could not be proved. The actuarial survival rate was 50% at 10 years of age, with a prolonged plateau thereafter. There was no difference in survival rates between patients with X-linked and those with autosomal recessive chronic granulomatous disease. The 8-year actuarial survival rate was significantly higher for patients born in 1978 or afterward than for patients born before 1978 (92.9% vs 70.5%). A retrospective analysis of the occurrence of bacterial and fungal infections in patients who received trimethoprim-sulfamethoxazole and ketoconazole as infection prophylaxis indicated that the former was effective against bacterial infections but that ketoconazole provided no protection against Aspergillus infections.
Mouy
R
R
Department of Pediatrics, Hôpital des Enfants-Malades, Paris, France.
Fischer
A
A
Vilmer
E
E
Seger
R
R
Griscelli
C
C
D000293:Adolescent; D001424:Bacterial Infections / Q000209:etiology* / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations / Q000627:therapeutic use; D008040:Genetic Linkage; D006105:Granulomatous Disease, Chronic / Q000150:complications* / Q000235:genetics / Q000401:mortality; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007654:Ketoconazole / Q000627:therapeutic use; D009181:Mycoses / Q000209:etiology* / Q000517:prevention & control; D010297:Paris; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014960:X Chromosome
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D007654:Ketoconazole